Abstract

With the incorporation of targeted therapies in routine cancer therapy, it is imperative that the array of toxicities associated with these agents be well-recognized and managed, especially since these toxicities are distinct from those seen with conventional cytotoxic agents. This review will focus on these renal toxicities from commonly used targeted agents. This review discusses the mechanisms of these side effects and management strategies. Anti-vascular endothelial growth factor (VEGF) agents including the monoclonal antibody bevacizumab, aflibercept (VEGF trap), and anti-VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKIs) all cause hypertension, whereas some of them result in proteinuria. Monoclonal antibodies against the human epidermal growth factor receptor (HER) family of receptors, such as cetuximab and panitumumab, cause electrolyte imbalances including hypomagnesemia and hypokalemia due to the direct nephrotoxic effect of the drug on renal tubules. Cetuximab may also result in renal tubular acidosis. The TKIs, imatinib and dasatinib, can result in acute or chronic renal failure. Rituximab, an anti-CD20 monoclonal antibody, can cause acute renal failure following initiation of therapy because of the onset of acute tumor lysis syndrome. Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, can result in proteinuria. Discerning the renal adverse effects resulting from these agents is essential for safe treatment strategies, particularly in those with pre-existing renal disease.

Original languageEnglish (US)
Pages (from-to)487-499
Number of pages13
JournalTargeted Oncology
Volume10
Issue number4
DOIs
StatePublished - Dec 1 2015

Fingerprint

Kidney
Monoclonal Antibodies
Proteinuria
Acute Kidney Injury
Protein-Tyrosine Kinases
Vascular Endothelial Growth Factor A
Tumor Lysis Syndrome
Renal Tubular Acidosis
Vascular Endothelial Growth Factor Receptor
Preexisting Condition Coverage
Hypokalemia
Cytotoxins
Sirolimus
Therapeutics
Epidermal Growth Factor Receptor
Electrolytes
Chronic Kidney Failure
Hypertension
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Renal Toxicities of Targeted Therapies. / Abbas, Anum; Mirza, Mohsin M.; Ganti, Apar Kishor P; Tendulkar, Ketki K.

In: Targeted Oncology, Vol. 10, No. 4, 01.12.2015, p. 487-499.

Research output: Contribution to journalArticle

Abbas, Anum ; Mirza, Mohsin M. ; Ganti, Apar Kishor P ; Tendulkar, Ketki K. / Renal Toxicities of Targeted Therapies. In: Targeted Oncology. 2015 ; Vol. 10, No. 4. pp. 487-499.
@article{76ed111335a8433199d322b05f5d73cc,
title = "Renal Toxicities of Targeted Therapies",
abstract = "With the incorporation of targeted therapies in routine cancer therapy, it is imperative that the array of toxicities associated with these agents be well-recognized and managed, especially since these toxicities are distinct from those seen with conventional cytotoxic agents. This review will focus on these renal toxicities from commonly used targeted agents. This review discusses the mechanisms of these side effects and management strategies. Anti-vascular endothelial growth factor (VEGF) agents including the monoclonal antibody bevacizumab, aflibercept (VEGF trap), and anti-VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKIs) all cause hypertension, whereas some of them result in proteinuria. Monoclonal antibodies against the human epidermal growth factor receptor (HER) family of receptors, such as cetuximab and panitumumab, cause electrolyte imbalances including hypomagnesemia and hypokalemia due to the direct nephrotoxic effect of the drug on renal tubules. Cetuximab may also result in renal tubular acidosis. The TKIs, imatinib and dasatinib, can result in acute or chronic renal failure. Rituximab, an anti-CD20 monoclonal antibody, can cause acute renal failure following initiation of therapy because of the onset of acute tumor lysis syndrome. Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, can result in proteinuria. Discerning the renal adverse effects resulting from these agents is essential for safe treatment strategies, particularly in those with pre-existing renal disease.",
author = "Anum Abbas and Mirza, {Mohsin M.} and Ganti, {Apar Kishor P} and Tendulkar, {Ketki K}",
year = "2015",
month = "12",
day = "1",
doi = "10.1007/s11523-015-0368-7",
language = "English (US)",
volume = "10",
pages = "487--499",
journal = "Targeted Oncology",
issn = "1776-2596",
publisher = "Springer Paris",
number = "4",

}

TY - JOUR

T1 - Renal Toxicities of Targeted Therapies

AU - Abbas, Anum

AU - Mirza, Mohsin M.

AU - Ganti, Apar Kishor P

AU - Tendulkar, Ketki K

PY - 2015/12/1

Y1 - 2015/12/1

N2 - With the incorporation of targeted therapies in routine cancer therapy, it is imperative that the array of toxicities associated with these agents be well-recognized and managed, especially since these toxicities are distinct from those seen with conventional cytotoxic agents. This review will focus on these renal toxicities from commonly used targeted agents. This review discusses the mechanisms of these side effects and management strategies. Anti-vascular endothelial growth factor (VEGF) agents including the monoclonal antibody bevacizumab, aflibercept (VEGF trap), and anti-VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKIs) all cause hypertension, whereas some of them result in proteinuria. Monoclonal antibodies against the human epidermal growth factor receptor (HER) family of receptors, such as cetuximab and panitumumab, cause electrolyte imbalances including hypomagnesemia and hypokalemia due to the direct nephrotoxic effect of the drug on renal tubules. Cetuximab may also result in renal tubular acidosis. The TKIs, imatinib and dasatinib, can result in acute or chronic renal failure. Rituximab, an anti-CD20 monoclonal antibody, can cause acute renal failure following initiation of therapy because of the onset of acute tumor lysis syndrome. Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, can result in proteinuria. Discerning the renal adverse effects resulting from these agents is essential for safe treatment strategies, particularly in those with pre-existing renal disease.

AB - With the incorporation of targeted therapies in routine cancer therapy, it is imperative that the array of toxicities associated with these agents be well-recognized and managed, especially since these toxicities are distinct from those seen with conventional cytotoxic agents. This review will focus on these renal toxicities from commonly used targeted agents. This review discusses the mechanisms of these side effects and management strategies. Anti-vascular endothelial growth factor (VEGF) agents including the monoclonal antibody bevacizumab, aflibercept (VEGF trap), and anti-VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKIs) all cause hypertension, whereas some of them result in proteinuria. Monoclonal antibodies against the human epidermal growth factor receptor (HER) family of receptors, such as cetuximab and panitumumab, cause electrolyte imbalances including hypomagnesemia and hypokalemia due to the direct nephrotoxic effect of the drug on renal tubules. Cetuximab may also result in renal tubular acidosis. The TKIs, imatinib and dasatinib, can result in acute or chronic renal failure. Rituximab, an anti-CD20 monoclonal antibody, can cause acute renal failure following initiation of therapy because of the onset of acute tumor lysis syndrome. Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, can result in proteinuria. Discerning the renal adverse effects resulting from these agents is essential for safe treatment strategies, particularly in those with pre-existing renal disease.

UR - http://www.scopus.com/inward/record.url?scp=84949103875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949103875&partnerID=8YFLogxK

U2 - 10.1007/s11523-015-0368-7

DO - 10.1007/s11523-015-0368-7

M3 - Article

VL - 10

SP - 487

EP - 499

JO - Targeted Oncology

JF - Targeted Oncology

SN - 1776-2596

IS - 4

ER -